Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$0.25
>-$0.01(-0.40%)
At close: 4:00 PM EDT
$0.25
>-$0.01(-0.40%)
Day’s Range― - ―
52-Week Range$0.19 - $2.98
Previous CloseN/A
Volume270.87K
Average Volume (3M)1.19M
Market Cap
$6.88M
Enterprise Value-$1.18
Total Cash (Recent Filing)$9.96M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding30,442,139
10 Day Avg. Volume743,535
30 Day Avg. Volume1,188,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.25Price Target Upside1600.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
Bulls Say, Bears Say
Bulls Say
Clinical Manufacturing ReadinessExpanded manufacturing capacity and transferred test methods can improve supply reliability for ongoing and planned trials, reducing operational bottlenecks as AIM advances Ampligen toward larger clinical studies.
Listing Compliance And Capital SupportRestored exchange compliance and recently raised capital provide near-term organizational stability and funding for development activities, while reducing the immediate risk that listing problems disrupt access to investors.
Diversified Ampligen PipelineA platform spanning pancreatic cancer and emerging viral threats gives Ampligen multiple potential development paths. Orphan designations and prior safety data may support specialized regulatory and partnership opportunities, though efficacy remains unproven.
Bears Say
Minimal Revenue And Deep LossesA minimal revenue base and deeply negative gross, operating, and net profitability show that AIM has not established a commercial economic model. Sustained losses increase dependence on financing while clinical programs remain unproven.
Persistent Cash BurnConsistently negative operating and free cash flow means research, manufacturing, and trial spending are not funded internally. Continued cash burn could constrain development pace and require repeated external capital over the next several quarters.
Dilution And Financing DependenceBroad authorization for warrant, note-related, and other equity issuance preserves funding access but creates substantial dilution risk. The reverse-split flexibility and prior equity instability also indicate continuing dependence on capital markets.
AIM ImmunoTech News
AIM FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was $0.19 and its highest was $2.98 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $6.88M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 17, 2027 which is in 349 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 10, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.26.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 30,442,139 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -7.719%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM Stock 12 Month Forecast
Average Price Target
$4.25
▲(1600.00% Upside)
Technical Analysis
Ownership Overview
0.30% Insiders
0.09% Mutual Funds
0.04% Other Institutional Investors
99.56% Public Companies and
Individual Investors